Prevalence and predictors of kaposi sarcoma herpes virus seropositivity: a cross-sectional analysis of HIV-infected adults initiating ART in Johannesburg, South Africa.
Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study.
Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance.
Autorzy:
Salata RA; Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH, 44122, USA. . Grinsztejn B; Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil. Ritz J; Harvard T.H. Chan School of Public Health, Boston, MA, USA. Collier AC; University of Washington, Seattle, WA, USA. Hogg E; Social & Scientific Systems, A DLH Company, MD, Silver Spring, USA. Gross R; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. Godfrey C; NIAID, Bethesda, MD, USA. Kumarasamy N; YR Gaitonde Center for AIDS Research and Education, Chennai, India. Kanyama C; University of North Carolina Project-Malawi, Lilongwe, Malawi. Mellors JW; University of Pittsburgh, Pittsburgh, PA, USA. WallisCL; Lancet Laboratories and BARC SA, Johannesburg, South Africa. Hughes MD; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
Autorzy:
Avihingsanon A; HIV-NAT, Thai Red Cross AIDS Research Centre and Centre of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Hughes MD; Center for Biostatistics in AIDS Research in the Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, Massachusetts, USA. Salata R; Case Western Reserve University, Cleveland, Ohio, USA. Godfrey C; Division of AIDS, National Institutes of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USA. McCarthy C; Center for Biostatistics in AIDS Research in the Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, Massachusetts, USA. Mugyenyi P; Joint Clinical Research Center, Kampala, Uganda. Hogg E; Social & Scientific Systems, Inc., a DLH Holdings Company, Silver Spring, Maryland, USA. Gross R; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Cardoso SW; Instituto Nacional de Infectologia Evandro Chagas, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil. Bukuru A; Joint Clinical Research Center, Kampala, Uganda. Makanga M; Kenya Medical Research Institute/Center of Disease Control, Kisumu, Kenya. Badal-Aesen S; Clinical HIV Research Unit, Helen Joseph Hospital, University of Witwatersrand, Johannesburg, South Africa. Mave V; BJ Medical College Clinical Research Site, Pune, India. Ndege BW; Moi University Clinical Research Center (MUCRC) CRS, Eldoret, Kenya. Fontain SN; Les Centres GHESKIO Clinical Research Site, Port-au-Prince, Haiti. Samaneka W; University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe. Secours R; Les Centres GHESKIO Clinical Research Site, Port-au-Prince, Haiti. Van Schalkwyk M; Family Centre for Research with Ubuntu (FAMCRU), Stellenbosch University, Cape Town, South Africa. Mngqibisa R; Durban International Clinical Research Site, King Edward Hospital, Enhancing Care Foundation, Durban, South Africa. Mohapi L; Soweto AIDS Clinical Trials Group, Clinical Research Site, Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa. Valencia J; Barranco Clinical Research Site, Lima, Peru. Sugandhavesa P; Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand. Montalban E; San Miguel Clinical Research Site, Lima, Peru. Munyanga C; University of North Carolina Project, Kamazu Central Hospital, Lilongwe, Malawi. Chagomerana M; University of North Carolina Project, Kamazu Central Hospital, Lilongwe, Malawi. Santos BR; Hospital Nossa Senhora da Conceicao CRS, Porto Alegre, Brazil. Kumarasamy N; CART, Clinical Research Site, VHS Infection Disease Medical Centre, Chennai, India. Kanyama C; University of North Carolina Project, Kamazu Central Hospital, Lilongwe, Malawi. Schooley RT; Division of Infectious Diseases, University of California, San Diego, California, USA. Mellors JW; Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. WallisCL; BARC-South Africa and Lancet Laboratories, Johannesburg, South Africa. Collier AC; University of Washington School of Medicine, University of Washington, Seattle, Washington, USA. Grinsztejn B; Instituto Nacional de Infectologia Evandro Chagas, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil.
Southern African guidelines on the safe, easy and effective use of pre-exposure prophylaxis: 2020.
Autorzy:
Bekker LG; Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa. Brown B; Anova Health Institute, Johannesburg, South Africa. Joseph-Davey D; Department of Epidemiology, University of California, Los Angeles, United States of America.; Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. Gill K; Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa. Moorhouse M; Wits Reproductive Health and HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa. Delany-Moretlwe S; Wits Reproductive Health and HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa. Myer L; Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. Orrell C; Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.; Department of Medicine, University of Cape Town, Cape Town, South Africa. Rebe K; Life Vincent Pallotti Hospital, Cape Town, South Africa.; Department of Medicine and Infectious Diseases, University of Cape Town, Cape Town, South Africa. Venter WDF; Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. WallisCL; BARC-SA, Speciality Molecular Division, Lancet Laboratories, Johannesburg, South Africa.
Pokaż więcej
Źródło:
Southern African journal of HIV medicine [South Afr J HIV Med] 2020 Dec 10; Vol. 21 (1), pp. 1152. Date of Electronic Publication: 2020 Dec 10 (Print Publication: 2020).
Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy.
Autorzy:
Mahomed K; Private practice, Johannesburg, South Africa. WallisCL; Department of Molecular Pathology, BARC-SA and Lancet Laboratories, Johannesburg, South Africa. Dunn L; Aid for AIDS Management (Pty) Ltd, Cape Town, South Africa. Maharaj S; Aid for AIDS Management (Pty) Ltd, Cape Town, South Africa. Maartens G; Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. Meintjes G; Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Pokaż więcej
Źródło:
Southern African journal of HIV medicine [South Afr J HIV Med] 2020 Jul 02; Vol. 21 (1), pp. 1062. Date of Electronic Publication: 2020 Jul 02 (Print Publication: 2020).
Cryptococcal antigenemia is associated with meningitis or death in HIV-infected adults with CD4 100-200 cells/mm .
Autorzy:
Wykowski J; Department of Medicine, University of Washington, Seattle, USA. . Galagan SR; Global Health, University of Washington, Seattle, USA. Govere S; AIDS Healthcare Foundation, Durban, South Africa. WallisCL; BARC-SA and Lancet Laboratory, Johannesburg, South Africa. Moosa MY; Department of Infectious Diseases, University of KwaZulu-Natal, Durban, South Africa. Celum C; Department of Medicine, University of Washington, Seattle, USA.; Global Health, University of Washington, Seattle, USA. Drain PK; Department of Medicine, University of Washington, Seattle, USA.; Global Health, University of Washington, Seattle, USA.; Epidemiology, University of Washington, Seattle, USA.
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2020 Jan 20; Vol. 20 (1), pp. 61. Date of Electronic Publication: 2020 Jan 20.
Distinct rates and patterns of spread of the major HIV-1 subtypes in Central and East Africa.
Autorzy:
Faria NR; Department of Zoology, University of Oxford, Oxford, United Kingdom. Vidal N; TransVIHMI, Institut de Recherche pour le Développement, INSERM, and University of Montpellier, Montpellier, France. Lourenco J; Department of Zoology, University of Oxford, Oxford, United Kingdom. Raghwani J; Department of Zoology, University of Oxford, Oxford, United Kingdom. Sigaloff KCE; Amsterdam Institute for Global Health and Development, Department of Global Health, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.; Department of Internal Medicine, Section of Infectious Diseases, VU University Medical Center, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands. Tatem AJ; Department of Geography and Environment, University of Southampton, Southampton, United Kingdom.; Flowminder Foundation, Stockholm, Sweden. van de Vijver DAM; Viroscience Department, Erasmus Medical Center, Rotterdam, The Netherlands. Pineda-Peña AC; Global Health and Tropical Medicine-Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisboa, Portugal.; Molecular Biology and Immunology Department, Fundación Instituto de Inmunología de Colombia, Basic Sciences Department, Universidad del Rosario, Bogotá, Colombia. Rose R; Bioinfoexperts, LLC, Thibodaux, Los Angeles, United States of America. WallisCL; Department of Molecular Pathology, Lancet Laboratories and BARC-SA, Johannesburg, South Africa. Ahuka-Mundeke S; Institut National de Recherche Biomedicales, Kinshasa, Democratic Republic of Congo and Service de Microbiologie, Cliniques Universitaires de Kinshasa, Kinshasa, Democratic Republic of Congo. Muyembe-Tamfum JJ; Institut National de Recherche Biomedicales, Kinshasa, Democratic Republic of Congo and Service de Microbiologie, Cliniques Universitaires de Kinshasa, Kinshasa, Democratic Republic of Congo. Muwonga J; AIDS national laboratory and Service de Microbiologie, Cliniques Universitaires de Kinshasa, Kinshasa, Democratic Republic of Congo. Suchard MA; Departments of Biomathematics and Human Genetics David Geffen School of Medicine at UCLA, and Department of Biostatistics UCLA School of Public Health, Los Angeles, United States of America. Rinke de Wit TF; Amsterdam Institute for Global Health and Development, Department of Global Health, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands. Hamers RL; Amsterdam Institute for Global Health and Development, Department of Global Health, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands. Ndembi N; Institute of Human Virology, Abuja, Nigeria. Baele G; KU Leuven, Department of Microbiology and Immunology, Rega Institute, Laboratory for Clinical and Epidemiological Virology, Leuven, Belgium. Peeters M; TransVIHMI, Institut de Recherche pour le Développement, INSERM, and University of Montpellier, Montpellier, France. Pybus OG; Department of Zoology, University of Oxford, Oxford, United Kingdom. Lemey P; KU Leuven, Department of Microbiology and Immunology, Rega Institute, Laboratory for Clinical and Epidemiological Virology, Leuven, Belgium. Dellicour S; KU Leuven, Department of Microbiology and Immunology, Rega Institute, Laboratory for Clinical and Epidemiological Virology, Leuven, Belgium.; Spatial Epidemiology Lab, Université Libre de Bruxelles, Bruxels, Belgium.
Pokaż więcej
Źródło:
PLoS pathogens [PLoS Pathog] 2019 Dec 06; Vol. 15 (12), pp. e1007976. Date of Electronic Publication: 2019 Dec 06 (Print Publication: 2019).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
Validation of clinic-based cryptococcal antigen lateral flow assay screening in HIV-infected adults in South Africa.
Autorzy:
Drain PK; Departments of Global Health, University of Washington, Seattle, USA. .; Medicine, University of Washington, Seattle, USA. .; Epidemiology, University of Washington, Seattle, USA. . Hong T; Departments of Global Health, University of Washington, Seattle, USA. Krows M; Departments of Global Health, University of Washington, Seattle, USA. Govere S; AIDS Healthcare Foundation, Durban, South Africa. Thulare H; AIDS Healthcare Foundation, Durban, South Africa. WallisCL; BARC-SA and Lancet Laboratory, Johannesburg, South Africa. Gosnell BI; Department of Infectious Diseases, University of KwaZulu-Natal, Durban, South Africa. Moosa MY; Department of Infectious Diseases, University of KwaZulu-Natal, Durban, South Africa. Bassett IV; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA. Celum C; Departments of Global Health, University of Washington, Seattle, USA.; Medicine, University of Washington, Seattle, USA.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2019 Feb 25; Vol. 9 (1), pp. 2687. Date of Electronic Publication: 2019 Feb 25.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.
Autorzy:
Paredes R; IrsiCaixa AIDS Research Institute, Badalona, Spain. Tzou PL; Division of Infectious Diseases, Stanford University, Stanford, CA, United States of America. van Zyl G; Division of Medical Virology, Stellenbosch University and NHLS Tygerberg, Cape Town, South Africa. Barrow G; Centre for HIV/AIDS Research, Education and Services (CHARES), Department of Medicine, University of the West Indies, Kingston Jamaica. Camacho R; Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium. Carmona S; Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa. Grant PM; Division of Infectious Diseases, Stanford University, Stanford, CA, United States of America. Gupta RK; UCL, Department of Infection, London, WC1E 6BT, United Kingdom. Hamers RL; Amsterdam Institute for Global Health and Development, Department of Global Health, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands. Harrigan PR; BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada. Jordan MR; Tufts University School of Medicine, Boston, MA, United States of America. Kantor R; Division of Infectious Diseases, Alpert Medical School, Brown University, Providence, RI, United States of America. Katzenstein DA; Division of Infectious Diseases, Stanford University, Stanford, CA, United States of America. Kuritzkes DR; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States of America. Maldarelli F; HIV Dynamics and Replication Program, CCR, National Cancer Institute, NIH, Translational Research Unit, Frederick, MD, United States of America. Otelea D; Molecular Diagnostics Laboratory, National Institute for Infectious Diseases, Bucharest, Romania. WallisCL; BARC-SA and Lancet Laboratories, Johannesburg, South Africa. Schapiro JM; National Hemophilia Center, Tel Hashomer, Israel. Shafer RW; Division of Infectious Diseases, Stanford University, Stanford, CA, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2017 Jul 28; Vol. 12 (7), pp. e0181357. Date of Electronic Publication: 2017 Jul 28 (Print Publication: 2017).
The use of digital PCR to improve the application of quantitative molecular diagnostic methods for tuberculosis.
Autorzy:
Devonshire AS; Molecular and Cell Biology, LGC, Queens Road, Teddington, TW11 0LY, UK. O'Sullivan DM; Molecular and Cell Biology, LGC, Queens Road, Teddington, TW11 0LY, UK. Honeyborne I; Centre for Clinical Microbiology, Department of Infection, University College London, Royal Free Campus, London, UK. Jones G; Molecular and Cell Biology, LGC, Queens Road, Teddington, TW11 0LY, UK. Karczmarczyk M; European Commission, Joint Research Centre (JRC), Institute for Reference Materials and Measurements (IRMM), Geel, Belgium. Pavšič J; National Institute of Biology, Večna pot 111, 1000, Ljubljana, Slovenia. Gutteridge A; Molecular and Cell Biology, LGC, Queens Road, Teddington, TW11 0LY, UK. Milavec M; National Institute of Biology, Večna pot 111, 1000, Ljubljana, Slovenia. Mendoza P; Vircell S.L. Molecular Diagnostic Department, The Technology Park of Health Sciences, Granada, Spain. Schimmel H; European Commission, Joint Research Centre (JRC), Institute for Reference Materials and Measurements (IRMM), Geel, Belgium. Van Heuverswyn F; European Commission, Joint Research Centre (JRC), Institute for Reference Materials and Measurements (IRMM), Geel, Belgium. Gorton R; Centre for Clinical Microbiology, Department of Infection, University College London, Royal Free Campus, London, UK. Cirillo DM; TB Supranational Reference Laboratory, San Raffaele Scientific Institute, Milan, Italy. Borroni E; TB Supranational Reference Laboratory, San Raffaele Scientific Institute, Milan, Italy. Harris K; Microbiology, Virology and Infection Control, Great Ormond Street Hospital NHS Foundation Trust, London, UK. Barnard M; Centre for Clinical Tuberculosis Research, TASK Applied Science, Cape Town, South Africa.; SA MRC Centre for TB Research, DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences - Stellenbosch University, Francie van Zijl Drive, Tygerberg 7505, PO Box 241, Cape Town, 8000, South Africa. Heydenrych A; Centre for Clinical Tuberculosis Research, TASK Applied Science, Cape Town, South Africa.; SA MRC Centre for TB Research, DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences - Stellenbosch University, Francie van Zijl Drive, Tygerberg 7505, PO Box 241, Cape Town, 8000, South Africa. Ndusilo N; KCRI, Moshi, Tanzania. WallisCL; BARC-SA and Mycobacteriology Department, Lancet Laboratories, Johannesburg, South Africa. Pillay K; BARC-SA and Mycobacteriology Department, Lancet Laboratories, Johannesburg, South Africa. Barry T; Nucleic Acid Diagnostics Research Laboratory (NADRL), Microbiology, School of Natural Sciences, National University of Ireland, Galway, Ireland. Reddington K; Nucleic Acid Diagnostics Research Laboratory (NADRL), Microbiology, School of Natural Sciences, National University of Ireland, Galway, Ireland. Richter E; Forschungszentrum Borstel, National Reference Centre for Mycobacteria, Borstel, D-23845, Germany. Mozioğlu E; UME, Ulusal Metroloji Enstitüsü, Gebze, Kocaeli, Turkey. Akyürek S; UME, Ulusal Metroloji Enstitüsü, Gebze, Kocaeli, Turkey. Yalçınkaya B; UME, Ulusal Metroloji Enstitüsü, Gebze, Kocaeli, Turkey. Akgoz M; UME, Ulusal Metroloji Enstitüsü, Gebze, Kocaeli, Turkey. Žel J; National Institute of Biology, Večna pot 111, 1000, Ljubljana, Slovenia. Foy CA; Molecular and Cell Biology, LGC, Queens Road, Teddington, TW11 0LY, UK. McHugh TD; Centre for Clinical Microbiology, Department of Infection, University College London, Royal Free Campus, London, UK. Huggett JF; Molecular and Cell Biology, LGC, Queens Road, Teddington, TW11 0LY, UK. .; Centre for Clinical Microbiology, Department of Infection, University College London, Royal Free Campus, London, UK. .; School of Biosciences & Medicine, Faculty of Health & Medical Sciences, University of Surrey, Guildford, UK. .
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2016 Aug 03; Vol. 16, pp. 366. Date of Electronic Publication: 2016 Aug 03.
Predicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithm.
Autorzy:
Rutstein SE; Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Sarah_.; Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Sarah_. Hosseinipour MC; Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; UNC Project, Lilongwe, Malawi. Weinberger M; Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Wheeler SB; Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Biddle AK; Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. WallisCL; BARC-SA and Lancet Laboratories, Johannesburg, South Africa. Balakrishnan P; YRG Centre for AIDS Research and Education (YRG CARE), Voluntary Health Services, Taramani, Chennai, 600113, India. Mellors JW; Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, USA. Morgado M; Department of STD, AIDS, and Viral Hepatitis, Brazilian National STD and AIDS Program, Rio de Janeiro, Brazil. Saravanan S; YRG Centre for AIDS Research and Education, Chennai, India. Tripathy S; Institute for Leprosy and Other Mycobacterial Diseases, Tajganj, Agra, India. Vardhanabhuti S; Harvard T.H. Chan School of Public Health, Boston, MA, USA. Eron JJ; Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Miller WC; Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2016 Jun 13; Vol. 16, pp. 280. Date of Electronic Publication: 2016 Jun 13.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.
Autorzy:
Rhee SY; Department of Medicine, Stanford University, Stanford, CA, United States of America. Jordan MR; Tufts University School of Medicine, Boston, MA, United States of America. Raizes E; Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, GA, United States of America. Chua A; Medecins Sans Frontieres, Access Campaign, Geneva, Switzerland.; Institute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital, Singapore, Singapore. Parkin N; Data First Consulting, Belmont, CA, United States of America. Kantor R; Alpert Medical School, Brown University, Providence, RI, United States of America. Van Zyl GU; National Health Laboratory Service, Tygerberg, Coastal Branch, South Africa.; Division of Medical Virology, Stellenbosch University, Parow, South Africa. Mukui I; National AIDS and Sexually Transmitted Infection (STI) Control Programme, Ministry of Health, Nairobi, Kenya. Hosseinipour MC; UNC Project, Lilongwe, Malawi. Frenkel LM; University of Washington and Seattle Children's Research Institute, Seattle, WA, United States of America. Ndembi N; Institute of Human Virology, Abuja, Nigeria. Hamers RL; Amsterdam Institute for Global Health and Development (AIGHD), Department of Global Health, Academic Medical Center of the University of Amsterdam, Amsterdam, Netherlands. Rinke de Wit TF; Amsterdam Institute for Global Health and Development (AIGHD), Department of Global Health, Academic Medical Center of the University of Amsterdam, Amsterdam, Netherlands. WallisCL; Lancet Laboratories and BARC-SA, Johannesburg, South Africa. Gupta RK; Department of Infection, University College London, London, United Kingdom. Fokam J; Chantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management, Yaoundé, Cameroon.; Faculty of Medicine and Biomedical Sciences (FMBS) of the University of Yaounde 1, Yaounde, Cameroon. Zeh C; Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America. Schapiro JM; National Hemophilia Center, Tel Hashomer, Israel. Carmona S; Department of Haematology and Molecular Medicine, University of Witwatersrand, Johannesburg, South Africa.; National Health Laboratory Services, Johannesburg, South Africa. Katzenstein D; Department of Medicine, Stanford University, Stanford, CA, United States of America. Tang M; Department of Medicine, Stanford University, Stanford, CA, United States of America. Aghokeng AF; Virology Laboratory CREMER-IMPM, Yaoundé, Cameroon. De Oliveira T; Africa Centre for Health and Population Studies, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa. Wensing AM; Virology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands. Gallant JE; Southwest CARE Center, Santa Fe, NM, United States of America. Wainberg MA; McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada. Richman DD; Department of Pathology, University of California San Diego, La Jolla, CA, United States of America.; Veterans Affairs San Diego Healthcare System, San Diego, CA, United States of America. Fitzgibbon JE; Drug Development and Clinical Sciences Branch, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America. Schito M; HJF-DAIDS, A Division of The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America. Bertagnolio S; HIV Department WHO, Geneva, Switzerland. Yang C; Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, GA, United States of America. Shafer RW; Department of Medicine, Stanford University, Stanford, CA, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2015 Dec 30; Vol. 10 (12), pp. e0145772. Date of Electronic Publication: 2015 Dec 30 (Print Publication: 2015).
Stability of HIV-1 Nucleic Acids in Dried Blood Spot Samples for HIV-1 Drug Resistance Genotyping.
Autorzy:
Aitken SC; Department of Medical Microbiology, University Medical Centre Utrecht, Utrecht, The Netherlands. WallisCL; Lancet Laboratories, Johannesburg, South Africa. Stevens W; Department of Molecular Medicine and Hematology, University of the Witwatersrand, Johannesburg, South Africa; National Health Laboratory Services, Johannesburg, South Africa. de Wit TR; PharmAccess International, Amsterdam, The Netherlands; Global Health Department, Amsterdam Institute for Global Health and Development (AIGHD), Academic Medical Center, Amsterdam, the Netherlands. Schuurman R; Department of Medical Microbiology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2015 Jul 06; Vol. 10 (7), pp. e0131541. Date of Electronic Publication: 2015 Jul 06 (Print Publication: 2015).
Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
